COMPANY PROFILE

ICE Bioscience

Explore full profile

Integrated preclinical drug-discovery biology CRO

Chaoyang District, ChinaFounded 2010Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About ICE Bioscience

ICE Bioscience (北京爱思生物) is a Beijing-based integrated drug-discovery contract research organization founded in 2010. It provides target validation, hit finding, lead optimization, in-vitro and in-vivo pharmacology, early safety pharmacology and DMPK services for small molecules, antibodies, ADCs and PROTACs, serving global pharma and biotech sponsors. Public materials describe laboratories and commercial sites in Beijing, Shanghai, Xuzhou and Guiyang plus Singapore and Boston presence, engagement with 1,000+ partners and several hundred employees, backed by multiple Series A–C funding rounds from Chinese growth investors.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Chaoyang District, China
Employees: 5
Open positions: None listed
Dealroom signal: 55.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	May 2024	—	—	Alwin Capital · GG Capital · E-Town Capital	↗
SERIES B✓Equity / VC	Aug 2023	$14M	$55M	Everest Venture Capital · Addor Capital · Shanghai Yuanjin Herun Private Equity Fund Management · Alwin Capital	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ICE Bioscience website traffic

Latest recorded traffic for ICE Bioscience is 6.8K monthly website visits, up 23.6% over the last three months. ICE Bioscience's team declined 84.8% over the past year.

Latest monthly visits6.8K 3-month web change+23.6% 1-year team growth-84.8%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ENEnvoyaPolymer-Based Nanoparticles for Targeted delivery	Boston, United States	Operational	10	$2M	$8M
TGTongshu GeneA high-tech enterprise that focuses on scientific and technological innovation and focuses on precise molecular diagnosis of tumors	China	Operational
MIMicroMGxThe MGx platform technology, discovers new chemistry by harnessing the power of microbes	Chicago, United States	Operational
BPBio PaletteBio Palette aims to become a world-leading company in the field of microbiome therapeutics by using bacteria optimized by genome editing to modify and control microbiomes	Kobe, Japan	Operational
BIBiospinA biotechnology company developing solutions to protect people from pathogens	Singapore, Singapore	Operational
AVAvantGuardAvantGuard (formerly Halomine) manufactures and supplies high-performance and human-friendly antimicrobial coating materials and technology	Ithaca, United States	Operational
ACActXFocused on making patient genomic information that are useful in everyday medical practice	Seattle, United States	Operational
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational